OTCA18 Final Project Plan – Regional hyperthermia for high-risk soft tissue sarcoma treatment – now available
The Final OTCA18 Project Plan on 'Regional hyperthermia for high-risk soft tissue sarcoma treatment' is now available for access, together with comments from external experts, Haukeland Hospital, and manufacturers, and the relevant answers for each from the assessment team. Please access
The Haute Autorité de Santé (HAS), National Institute for Health and Care Excellence (NICE) & the Croatian Institute for Public Health (HZJZ) are pleased to share the following WP5 strand B draft outputs for an 8 week public consultation: REQueST (Registry Evaluation
We are pleased to announce that the collaborative rapid assessment, OTCA11, on "Custom-made or customisable 3D printed implants and cutting guides versus non-3D printed standard implants and cutting guides for improving outcome in patients undergoing knee, maxillofacial, or cranial surgery"
To accompany the upcoming EUnetHTA 2019 Assembly & Forum 0n 10-11th April in Amsterdam, a Welcome Guide has been developed to give participants and attendees a thorough overview of the event proceedings, practical information, and EUnetHTA's working activities. The guide is
EUnetHTA has developed documentation to address Conflict of Interest (COI) concerns and assist in the decision-making process relating to the assessment of individuals potentially involved in EUnetHTA JA3 activities. The Procedure Guidance for handling Declaration of Interest (DOI) details how
EUnetHTA recently started a new Joint Assessment on a medicinal product for secondary progressive MS. To find out about participation, please read more here. Input submissions will be received through till EOB, April 28th.
The day's agenda is now available for the upcoming 2019 EUnetHTA Forum on 11th April at the West-Indisch Huis in central Amsterdam. We are looking forward to hosting a collaborative, informative session of talks that both outline progress made in European
Assessment Publication: Jointly Produced HTA Report; Partner Profile: Austria; Impact: Austria; Partner Profile: UK; Innovation & HTA: Giovanni Tafuri; Prioritisation List: Topics & Joint Assessments; 2018: Year in Review Download your copy HERE.
PTJA04 – “Sotagliflozin is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy” is now available
This is the assessment of the relative effectiveness of ‘Sotagliflozin is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have
Registration has now closed for the EUnetHTA 2019 Forum, held this year at the West-Indisch Huis in Amsterdam, the Netherlands, on 11 April 2019. Consisting of EUnetHTA Consortium partners, stakeholder groups, and other organisations involved in the activities of EUnetHTA JA3,